The purpose of this voluntary research study is to test the effectiveness of the Positive Affect Intervention Program in reducing mental health symptoms for families experiencing financial hardship.

In this study, you and your child will attend some virtual and in-person study visits over 8 months. You will complete some interviews and questionnaires virtually. You will be randomly assigned to either an 8-session prevention program or to receive weekly educational materials to read. You and your child will come to the lab for in-person visits both pre and post program. During these visits, your child will complete some EEG tasks, and you and your child will complete some interaction tasks where your respiratory and heart rate data will be collected. You and your child will also be asked to complete some short daily phone surveys at home.

480 dollars

This study will see if participants who have the addition of saruparib to their treatment will have a longer time period before/if their cancer spreads.

Before participating in the trial, p[otential; participants will need to sign a consent form to have their tumor tested for the BRCA mutation. If the participants have this mutation in their tumor, they will be invited to participate in this trial. While you are receiving treatment you will need to come to the clinic on certain days for treatment, getting safety assessments, collection of blood samples and to see how you are feeling. You will come to the clinic every four weeks. The treatment will last for 24 months

This study is comparing Pembrolizumab in combination with Sacituzumab Govitecan vs. standard treatment for individuals who have drug resistant advanced urolethial cancer

Participants will need to come to the clinic to meet with the study team and to sign a consent form. Once it has been determined that it is safe for you to participate, you will come into the clinic for treatment every 21 days, or depending upon the treatment arm you are assigned. You will continue to come into the clinic for treatment until the medication stops working, you no longer want to participate in the study or the document feels it is not safe for you to continue. You will be followed for up to five years to see how you are doing.

This is a Phase 2b clinical research study, which is investigating the use of 5-Aminolevulinic Acid (5-ALA) combined with a Low-Intensity Diffuse Ultrasound (LIDU) system for Sonodynamic Therapy (SDT) in patients with newly diagnosed glioblastoma. LIDU is the name of the investigational SDT device developed by Alpheus Medical. SDT includes the combination of a sonosensitizing drug, also known as a sonosensitizer, that will only be absorbed by tumor cells, and ultrasound to activate the sonosensitizer and cause damage to the tumor cells. The SDT tested in this study includes the oral drug 5-Aminolevulinic Acid (5-ALA) as an investigational sonosensitizer. This investigational treatment is being tested as a potential treatment for your cancer, SDT has been shown in previous cell and animal studies to potentially have an anti-cancer effect.

In this research study there will be two treatment groups. One treatment group will receive standard of care maintenance temozolomide with 5-ALA + SDT, you will have a 50% of receiving this treatment group. The other treatment group wll receive standard of care maintenance temozolomide with placebo, an oral solution that will look like and taste like 5-ALA but will have no active ingredients in it, and sham SDT, a program will be run on the SDT device that will look and sound the same, but will not deliver ultrasound, you will have a 50% chance of receiving this treatment group. If you are eligible for the study, and agree to participate you will be randomized, like the flip of a coin, to one of the two treatment groups, neither you nor your doctors will know which treatment group you have been assigned.

This trial is designed for patients who are newly diagnosed with multiple myeloma (MM) but who do not want or cannot have an autologous stem cell transplant. Teclistamab and talquetamab have been used alone along with other drugs in the treatment of MM. this study hopes to add either drug to a standard treatment for MM at time of diagnosis to see how effective it is in keeping the MM quiet conpared to standard treatment alone.

Participants must be willing to come to all clinic study visits. The first cycle of treatment the participant will be hospitalized to make sure they do not have any side effects. You will be treated every four weeks as an outpatient until the treatment no longer works. You should tell your study team all side effects you feel and all medication you are taking.

$54.00 per completed visit. A caregiver may receive compensation of the same amount.

The purpose of this study is to investigate the effects of replacing snacks high in saturated fats and added sugars with pecans on blood sugar control, heart health and diet quality in individuals with prediabetes. Participants will be randomized into one of two groups. Group 1 will consume 1.5 oz of pecans per day in place of normally consumed snacks high in saturated fat and added sugars for 16 weeks. Group 2 will be asked to continue consuming their current diet for 16 weeks. Measures will be taken to evaluate blood sugar, heart health and dietary intake at the beginning and 16 weeks later.

• The total time commitment for this study is approximately 4 months. It may take up to 7 months to complete the study from the time that you do the clinic screening visit. • During the study, we will ask you to consume 1.5 oz of pecans per day for 16 weeks, or to use provided gift cards to purchase and consume your usual snacks/diet. • You will be asked to come to the Penn State Research Kitchen on campus once a month for 16 weeks to pick up your pecans or gift cards. • We will draw blood from you several times during the study, once at screening, and on two consecutive days at the start and end of the study (total 5 times). • At the start and end of the study, we will also measure your blood pressure and perform non-invasive tests of artery health. • You will also be asked to wear a continuous glucose monitor (CGM) for 14 days—7 days before the first testing visit and 7 days at the end of the study. The CGM is a small sensor worn on your arm that measures your blood sugar every 15 minutes. You will need to attend a non-fasting visit to have the CGM fitted (2 visits total). • At the start and end of the study, we will ask you to collect 12 saliva samples over two days at home. • At the start and end of the study, we will collect a small hair sample from the back of your head. • You will also be asked to collect a stool sample at the beginning and end of the study (2 total). • Compensation for this study is up to $150

150

To see if the combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus SoC chemotherapy plus trastuzumab plus pembrolizumab is better in treating gastric or gastroesophageal junction cancer

Participants will need to come to the clinic twice before they are able to start study treatment. The first time is to sign a consent form allowing their tumor tissue that has been stored to be spent for testing. This test will look to see if the tissue has changes in it to see if the medication will work. If the tissue has the receptive changes a second consent form will be signed to participate in the study. You will need to have tests done to make sure it is safe for you to participate in the study. If the tests results determine that is it safe, you will begin treatment. The first month of treatment you will need to come to the clinic every week for blood tests and to see how you are feeling. After that you will need to come to the clinic once a month for treatment and blood tests. You will also have scans done at certain time in the study. Those scans will tell the doctor if the study treatment is working to make your cancer go away. You will stay on this treatment until it stops working. After that, you will come back to the clinic for two more visits to see how you are feeling.

To evaluate the long-term safety of AAV2-hAQP1 in participants with radiation-induced late xerostomia

Participants who were on the parent trial and did not receive actual drug will be invited to be treated and then rolled over into long term follow up. For those who were treated with actual drug will roll over into a long term follow up. Long term follow up participants will be followed up monthly for 5 years.

$60 per visit

This is a drug study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL).

All subjects on study will be treated with the medicine blinatumomab. Some subjects will also receive an additional medicine, nivolumab. Subjects will receive treatment on this study for about 1.5-2.5 months. Treatment is divided into 1-2 cycles. Before the start of therapy, patients will have a bone marrow evaluation for Immunophenotyping and will have their bone marrow tested for MRD on Day 36 of cycle 1 and Day 36 of cycle 2 during treatment.

To evaluate the effectiveness of omecamtiv mecarbil in reducing the number of heart failure events or hospitalizations in patients with severely reduced left ventricular ejection fraction <30%.

Participate in about 13 in-person visits over 3 years with bloodwork at each in-person visit, participate in about 9 brief remote phone call visits, questionnaires at 5 of the in-person visits over the first year, first visit electrocardiogram (EKG), first visit Echocardiogram (ECHO) if not completed within the last 6 months, willing to be randomized to take oral study medication or placebo for the duration of the study (about 3 years).

Up to $1,500

This is a human–robot interaction study that will examine how well a robot can learn to perform a coffee-brewing task with help from a human user. Participants will physically correct the robot’s movements when the robot is moving in the wrong way, and will complete a short survey about their experience.

Participants will complete one in-person session. They will stand next to a robotic arm, guide the robot through a coffee-brewing task under different conditions, give physical interactions, and complete a short survey about their experience.

20

This study explores how human emotions influence the choices they make in an interactive game involving monetary prizes. Participants will play 5 repeated rounds of a two-player decision-making game where, in each round, they choose either to cooperate with the other player or act in their own self-interest. The amount of money they earn depends on both their own choice and the choice of the other player in each round. Participants will not be able to see the person that they are playing with because a divider will separate the two. They will also not be told that the other “player” is actually a member of the research team who follows a predetermined pattern of choices in the repeated game. Throughout the study, participants will answer brief questions on their phone about how they are feeling,and they will wear a wrist worn device that measures natural changes in skin conductance, which reflects emotional arousal. By combining these self-reported feelings with physiological signals, the study aims to understand how emotions related to repeated decisions involving cooperation, self interest and monetary incentives.

Participants will attend one in-person session (20-30 minutes). They will wear a wrist device that records skin conductance (EDA) and complete brief online surveys about their mood. They will play a multi-round decision-making game involving monetary earnings with another player. Earnings will depend on both players choices summed over the rounds.

$4-$28

This will compare Dato-Dxd against docetaxel in previously treated advanced or metastatic non squamous NSCLC.

the first visit will be to sign a consent form to test for a specific biomarker in your archived tumor. If you have that biomarker you will then sign a consent form to participate in the study, if you wish. You will need to come to the clinic for bloodwork and scans to make sure it is safe for you to participate. If it is determined that it is safe for you to continue, you will come to the clinic every month for treatment of your cancer. These visit may also include seeing the doctor, having blood work and completing questionnaires.

$1200.00 You will only be compensated for completed visits.

The main purpose of this clinical trial is to determine whether early non-invasive ventilation (NIV) in individuals diagnosed with amyotrophic lateral sclerosis (ALS) is feasible and is associated with improved quality of life, symptoms, and carbon dioxide levels compared to usual care. Study subjects assigned to the “early NIV” group will start NIV earlier than subjects in the usual care group. The study population will included a total of 48 adults diagnosed with ALS at three Neurology ALS clinics in the United States. Subjects will participate in a total of 5 study visits over a 12-month period.

Once eligible, enrolled subjects are assigned to a group (early NIV or usual care), they will attend a total of 5 in person study visits at the ALS clinic over a 12-month period. At Visit 1, subjects will complete questionnaires and assessments and receive the initial study intervention. Follow-up visits at the ALS clinic will take place every 3 months (Visit 2/Month 3; Visit 3/Month 6; Visit 4/Month 9; Visit 5/Month 12) with the completion of questionnaires and assessments plus review of NIV data as applicable.

The purpose of this clinical research study is to learn more about the use of the investigational drug, deucrictibant, for the prevention and treatment of Acquired Angioedema due to C1 Inhibitor Deficiency (AAE-C1INH) attacks. The study consists of a Screening Phase (up to 10 weeks), followed by a 12-weeks Prophylaxis Treatment Phase (Part 1), an On-demand Treatment Phase (Part 2) and an Open-Label On-demand Treatment Phase (Part 3). These are all described below. If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 15 months (60 weeks). During this study you will be asked to complete an electronic diary daily. At the study visits you will have blood samples collected. Vital signs, EKGs, and physical exams will be performed.

If you decide to take part in this research study, you will have a screening phase (up to 10 weeks), followed by a 12-week Prophylaxis Treatment Phase (Part 1), an On-demand Treatment Phase (Part 2) and an Open-Label On-demand Treatment Phase (Part 3). If you provide your consent to take part in the study and you are declared eligible to participate, your overall study participation will last approximately 15 months (60 weeks). where you will have procedures to determine if you meet the requirements to be in the study. These include a physical exam and an electrocardiogram (ECG) which will measure the electrical activity of your heart. You will also be required to give blood and urine samples. You will also need to complete a daily electronic diary. If you are a woman who can have children, you will also need to take pregnancy tests.

This study examines how speakers change their language use as they age. Sociolinguistic interviews will be used to document and analyze features of English in Pennsylvania. Sociolinguistic interviews will be conducted between the investigator(s) and the participant(s). Participants will be invited to complete the recorded interviews at different intervals in time. The hypothesis is that language use will change as a speaker ages - as social pressures and lifestyle change, so will language.

In this study, the interviewer will ask you a series of questions about your life. The following are some example topics you may be asked about: Personal background (e.g., place of birth, school, work, family, life in Pennsylvania), Leisure, media, everyday life (e.g., hobbies, dreams, sports and social events) Life experiences (e.g., favorite childhood memories, experience during Covid lockdown) Personal beliefs (e.g., spirituality, superstitions) Language (e.g., thoughts about language use and change) The interview will be audio recorded (no video). You will also be asked to complete a background questionnaire so that we can learn more about your life. When filling out the background questionnaire, you are free to skip any questions you prefer not to answer. At the end of the study, we may ask you if you would be interested in being contacted for follow-up interviews.

$20.00

To determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma (RCC).

The patient will either get immune therapy (either 2 immune therapy drugs or immune therapy plus a VEGF targeted therapy), or get immune therapy plus radiation therapy. The radiation treatments will be given on 3 different days over the course of 1-3 weeks. Immune therapy will continue until it is no longer working. After the treatment is stopped, the doctor and study team will monitor the patient every 6 months for 5 years after treatment and then annually for 3 years.

This study will look at the safety and effectiveness of cannabigerol (CBG)/cannabidiol (CBD) in the treatment of chemotherapy induced peripheral neuropathy.

You must attend all scheduled study visits, tell the study doctor about all medications you are taking (including over-the-counter medicines), and let the study team know how you are feeling. Patients must come to clinic visits (about every 4 weeks) for health checks, blood tests and surveys, take the hemp oil (CBG/CBD) twice a day for 12 weeks, complete a drug diary, return unused oil on their next visit, and answer phone calls between visits.

$500.00 if substudy completed

This research aims to investigate how memory functions in cognitively healthy individuals by characterizing age-related differences in memory performance and cognitive processes.

Individuals will be asked to complete computer-based and paper-and-pencil tasks with a researcher. These tasks are designed to assess memory and cognition during a single session. This session can be separated at the request of the participant.

$10/hour

The study will evaluate the effectiveness and safety of ICOTROKINRA compared to placebo in participants with moderate to severe Crohn's disease. The participants will be randomized to one of three treatment groups in a 1:1:1 ration and will receive one of the two drug induction regimens versus placebo. At week I-12 of induction treatment (study 1 or study 2 induction), the participants will be evaluated, and if they achieved clinical response or clinical remission, they could then continue treatment in the Maintenance study for 40-weeks. The response to icotrokinra in the study participants will be evaluated by blood draws to test for biomarkers and PK, study symptoms questionnaires (e.g. stool frequency and pain), and colonoscopy with biopsies. They will also have the physical evaluations, ECG, suicidality assessment, pregnancy testing and monitoring of hypersensitivity reactions, along with test for tuberculosis and other infections. In both induction studies and in the maintenance treatment, participants will receive one of the icotrokinra dose or placebo daily oral pill. After the completion of maintenance treatment, the participants could enter open-label extension study for the 4 years. The screening of potential subject will take six weeks, and at least two in-person visits. Eligible participants who signed informed consent can be enrolled in the induction treatment phase, with visit day 0, week 2, week 4, week 8 and week 12. The safety follow-up visit will be held four weeks after the last dose for eligible participants. Dosing will be done on-site during these visits: day 0, and weeks 2, 4, 8, and 12 if starting the maintenance. Biopsy samples will be collected at the screening and week 12 of induction/start of maintenance. During the maintenance phase of treatment for the responders there will be eleven in-person visits including M-0. Colonoscopy exam will be done at M-12, and M-40 weeks to evaluate a response to the treatment.

Participants will be required to sign the informed consent. There will be at least two screening visits on-site. If eligible, participants will be required to attend five in-person visits, comply to the instructions by the study team, have colonoscopy and blood draws done, take medication daily. They will be asked to complete daily diaries of the disease symptoms. Other tests that will be done to ensure safety are ECG, physical exams, target exams, answer questions on tuberculosis and other infections, provide stool samples and urine pregnancy tests if applicable.

$3,122

The study will evaluate the safety and effectiveness of ICOTROKINRA treatment compared to placebo in participants with moderately to severely active ulcerative colitis. For the induction treatment (12 -weeks), the participants will be randomized to one of the two doses of drug icotrokinra or the placebo (2:1). At week 12 of induction, the participants will be evaluated, and clinical responders will be rerandomized to the drug treatment or placebo. Non-responders will not be randomized but could continue to the maintenance treatment (40-weeks). The study participants will have response to the treatment evaluated by blood draws to test for biomarkers and PK, study symptoms questionnaires (e.g. stool frequency and pain), and colonoscopy with biopsies. They will also have the physical evaluations, ECG, suicidality assessment, pregnancy testing and monitoring of hypersensitivity reactions, along with test for tuberculosis and other infections. The potential participants will enter screening process after they sign the informed consent. The screening for eligibility lasts six weeks and included at least two visits, the clinic visit, and the endoscopy with biopsies. If eligible for the treatment induction, five in-person visits will be held on day 0, week 2, week 4, week 8 and week 12. Except on the visit days, patients will dose at home per the team's instructions. The safety follow-up visit will be held four weeks after the last dose for eligible participants. If eligible to continue treatment after the 40-weeks of maintenance (eleven in-person visit), participants could receive treatment for another four years with in-person visits every eight weeks in the long-term extension. Endoscopy exam will be done at screening, week 12 (end of induction), week 40 (end of maintenance). or disease evaluation (ED)

Participants will be required to sign the informed consent and understand their responsibilities to participate. There will be at least two screening visits on-site. If eligible, participants will be required to attend five in-person visits during the induction treatment, comply to the instructions by the study team, have colonoscopy and blood draws done, take medication daily. They will be asked to complete daily diaries of the disease symptoms. Other tests that will be done to ensure safety are ECG, physical exams, target exams, answer questions on the topic of suicide, about tuberculosis and other infections, provide stool samples and urine pregnancy tests if applicable.

$3000

To determine whether induction IO and chemotherapy prior to CCRT+IO improves progression-free survival (PFS) compared to CCRT+IO alone.

The patient will either get induction therapy, chemoradiation with pembrolizumab, and pembrolizumab maintenance therapy for up to 2 years, or chemoradiation and pembrolizumab followed by pembrolizumab maintenance therapy for up to 2 years. Induction therapy means they will receive chemotherapy with cisplatin and paclitaxel once a week for 6 weeks, plus pembrolizumab every 3 weeks for 2 doses, before starting chemoradiation and pembrolizumab. After the patient finishes treatment, they will check the patient every 3 months for the first 2 years after treatment. After that, they will check every 6 months for 3 years. This means the patient will keep seeing their doctor for 5 years after treatment.

The study aims to quantify the effects of blue-enriched white light on cognitive performance.

There will be only one visit where participants will complete cognitive tasks and subjective evaluations of the indoor experimental space.

15

The purpose of this study is to understand if an investigational treatment (pasritamig) added to docetaxel for progressive metastatic hormone resistant prostate cancer will work better than docetaxel alone.

Participants must come to all study visits, take the medication as instructed, tell the study how you are feeling and tell the study team about any medications you are taking, especially over the counter medications.

The goal of this project is to understand how the brain supports semantics and how this changes as we grow older.

There will be one, in-person, 90-minute session that will include computer tasks and an MRI. All activities will be at the University Park Campus.

$40 and free parking

This project seeks to determine how e-cigarette (EC) physical design features, including those that allow the user to manipulate the quality and quantity of aerosols, affect exposure and toxicity from oxidants and other aerosol constituents.

Subjects will attend 8 study visits over the course of 14 weeks to collect various biological samples (such as blood draws, exhaled breath samples, saliva samples). They will be given a study provided e-cigarette that they will use during and between the study visits. There will also be surveys to complete throughout the study.

900

We are testing an experimental drug, ADX-324, as a potential new treatment to help prevent HAE attacks. We are doing this study to find out if an injection of ADX-324 once every 3 months or every 6 months under the skin (subcutaneous) is safe, and if it can reduce the severity and number of HAE attacks.

The total study duration is up to 8 months (up to 2 months for screening before the first dose of ADX-324 or placebo, one dose of ADX-324 or placebo at Day 1 and again 3 months later (Week 13), and follow-up visits for up to 6 months after the first dose). You will need to answer questions about your health/HAE attacks, provide blood samples, undergo routine urine laboratory tests, receive the trial drug, undergo electrocardiogram (ECG), complete questionnaires about the quality of your life, undergo physical exams, and provide HAE attack information.

Sleep and circadian problems are associated with deleterious social, emotional, and cognitive outcomes, yet are modifiable. This prospective study will adapt, optimize, and test an empirically supported behavioral intervention that addresses common sleep and circadian problems of autistic adults, who are at increased risk for mental health disorders, using a transdiagnostic approach. The knowledge gained from this study will address a critical need for accessible transdiagnostic sleep interventions for autistic adults, who experience a broad range of sleep and circadian problems at high rates and often lack access to specialty care treatment.

You will need to complete self-report assessments at baseline and post-treatment, as well as collect data at home for 2 weeks by wearing a physical activity monitor on your wrist, and completing sleep diaries (short questionnaires) each day. You will also need to complete 6 weekly 50 minute sessions delivered individually by trained clinicians. You will also complete a 30-minute semi-structured interview at post-treatment with the study coordinator.

$75.00

This study is comparing two treatments for the treatment of melanoma.

You will need to come to the clinic twice before start study treatment. The first time is to sign permission to send your tumor to be tested for specific changes. If those changes are in the tumor you will be brought back to the clinic and invited to participate in the study. After testing and scans are done to make sure it is safe for you to take part in the study, you will begin treatment. You will come to the clinic every 3-4 weeks for treatment. You will continue treatment until it no longer works, you no longer wish to receive treatment, or the study doctor feels it is not safe for you to continue.

$60.00 for each completed visit

The purpose of this study is to explore outdoor lighting and its environmental impact, focusing on human perception of these factors. Participants will undergo various tests to evaluate their subjective and objective responses to different light levels and chromaticities.

Participants will complete a demographic survey, will undergo screening tests to assess their visual acuity. If eligible, they will evaluate various lighting environments through a questionnaire and complete an object detection test before and after a brief training session. The total duration of the experiment will be approximately 1 hours.

$20